查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439708

敗血症診斷 - 全球市場考量、競爭格局、市場預測 (2030)

Sepsis Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

全球敗血症診斷市場規模預計到 2023 年將達到 6.4448 億美元，到 2030 年將達到 11.1482 億美元，2024-2030 年預測期間複合年增長率為 9.60%。 由於各種因素，如COVID-19 大流行的爆發、老年人口的增加、結核病等細菌感染的患病率增加，以及利用先進技術的膿毒症診斷產品的監管批准激增，市場出現了積極增長。我是。 因此，預計在 2024-2030 年預測期內，市場將以顯著的複合年增長率成長。

敗血症診斷的市場動態

敗血症診斷市場的主要驅動因素之一是 COVID-19 大流行的爆發。 根據世界衛生組織 (WHO) 2022 年 7 月 1 日發佈的數據，全球有 545,226,550 例確診的 COVID-19 病例。 因此，雖然 COVID-19 對呼吸系統有眾所周知的影響，大多數受害者因不同嚴重程度的肺炎而需要住院治療，但它仍然會影響大多數其他器官系統。 這與敗血症和直接病毒入侵的結合一致。 因此，敗血症診斷試圖檢查感染和器官損傷的跡象，這可能會推動對敗血症診斷的需求，並在預測期內（2024-2030年）推動整個敗血症診斷市場的發展。

根據世界衛生組織2023年發佈的數據，預計60歲以上人口將從2015年的12%至2050年翻一番，到2050年將達到21億。 此外，到2030年，世界上六分之一的人將超過60歲。 根據上述數據，2020年至2050年間，80歲及以上的人口預計將增加兩倍，達到4.26億人。 此外，隨著年齡的增長，我們的免疫系統減弱，感染的機會增加，這可能會增加對敗血症診斷的需求。 因此，老年人口的增加將增加對敗血症診斷的需求，這將成為預測期內（2024-2030年）推動整個敗血症診斷市場的一個因素。

因此，上述因素可能會增加對敗血症診斷的需求，並推動預測期內（2024-2030 年）敗血症診斷市場的整體成長。

然而，敗血症治療的高昂成本以及對敗血症的認識和知識的缺乏可能會阻礙全球敗血症診斷市場的成長。

持續的 COVID-19 大流行對敗血症診斷市場產生了輕微的正面影響。 根據全球敗血症聯盟的說法，SARS-CoV-2 會導致敗血症。 最近的研究證實了這一點，該研究表明病毒性敗血症是 COVID-19 患者最常見的併發症，並且與死亡率增加有關。 由於 COVID-19 影響患者的呼吸系統，因此大多數患者因不同嚴重程度的肺炎而需要住院治療；然而，大多數其他器官系統也可能受到影響。 這與敗血症和直接病毒入侵的結合一致。 因此，COVID-19大流行病例的快速增加將推動對膿毒症診斷的需求，而COVID-19病例的進一步增加將增加對膿毒症檢測中使用的工具、試劑和檢測試劑盒的需求，從而導致敗血症診斷的需求增加。整個敗血症診斷市場預計將快速成長。

敗血症診斷市場區隔分析

在膿毒症診斷市場的產品類型細分市場中，儀器和套件細分市場預計在 2024-2030 年預測期內將出現顯著增長。 例如，血液培養鑑定板（BCID）可以快速且準確地識別與血流感染相關的病原體和抗生素抗藥性基因。 它可以檢查多種病原體（24 種）以及與血液感染相關的三種抗生素抗性基因。 此外，只需大約一小時零兩分鐘的實際操作時間，只需一項測試就可以在 10 個陽性血液培養物中的 9 個中識別出感染。 因此，與 BCID 相關的好處可能會增加市場對儀器/套件的需求，並推動預測期內全球膿毒症診斷市場的整體成長。

本報告提供了全球膿毒症診斷市場的研究和分析，包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。

目錄

第1章膿毒症診斷市場報告簡介

第2章膿毒症診斷市場執行摘要

  • 調查範圍
  • 市場概覽
  • 競爭評估
  • 財務基準

第3章監理分析

  • 美國
  • 歐洲
  • 日本
  • 中國

第4章膿毒症診斷市場主要因素分析

  • 推動膿毒症診斷市場的因素
    • 新冠肺炎 (COVID-19) 疫情爆發
    • 老年人口增加
    • 結核病等細菌感染流行
    • 監管機構對採用先進技術的膿毒症診斷產品的批准激增
  • 敗血症診斷市場的限制與挑戰
    • 敗血症治療費用高昂
    • 缺乏對敗血症的認知與瞭解
  • 敗血症診斷市場機遇
    • 臨床和即時檢測新技術
    • 鑑定用於膿毒症診斷的新生物標記

第5章膿毒症診斷市場波特五力分析

第6章COVID-19對敗血症診斷市場的影響分析

第7章膿毒症診斷市場佈置

  • 依產品類型
    • 檢測/試劑
    • 設備/套件
  • 依技術型
    • 免疫分析
    • 分子診斷
    • 流式細胞儀
    • 微生物
    • 其他
  • 按檢定類型
    • 臨床檢查
    • 即時偵測
  • 依病原體分類
    • 細菌
    • 真菌
  • 按最終用戶
    • 醫院
    • 病理研究所
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他領域

第 8 章敗血症診斷市場：全球公司佔有率分析 - 3 至 5 家主要公司

第 9 章敗血症診斷市場公司與產品概況

  • BD
  • Cytovale (TM) Inc
  • Thermo Fisher Scientific Inc
  • Abbott
  • F. Hoffmann-La Roche Ltd
  • bioMerieux SA
  • Danaher
  • T2 Biosystems Inc
  • Luminex Corporation
  • Bruker
  • Immunexpress Inc
  • Axis-Shield Diagnostics Ltd
  • Quidel Corporation
  • Siemens Healthcare Private Limited
  • EKF Diagnostics Holdings plc
  • Seegene Inc
  • Boditech Med Inc
  • Alifax S.r.l. Italy
  • Koninklijke Philips N.V
  • Response Biomedical Corp

第10章KOL觀看次數

第 11 章專案方法

第 12 章關於 DelveInsight

第 13 章免責聲明與聯絡我們

Product Code: DIMDCL0552

Sepsis Diagnostics Market By Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, And Others), By Test Type (Laboratory Testing And Point Of Care Testing), By Product Type (Assays & Reagents And Instruments & Kits), By Pathogen (Bacterial, Fungal, And Others), By End-User (Hospitals, Pathology Laboratories, And Others), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to the increasing prevalence of covid-19 pandemic and a rise in the geriatric population

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030. The sepsis diagnostics market is witnessing positive growth owing to various factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products. Therefore, the market for sepsis diagnostics is estimated to grow at a significant CAGR during the forecast period from 2024 to 2030.

Sepsis Diagnostics Market Dynamics:

One of the main drivers of the sepsis diagnostics market is the increasing prevalence of the COVID-19 pandemic. According to the World Health Organization (WHO) data published on 1 July 2022, there have been 545,226,550 confirmed cases of COVID-19 all over the world. Thus, COVID-19 has well-known effects on the respiratory system, with the majority of victims requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Therefore, sepsis diagnosis is attempted to verify or check the signs of any infection or organ damage with the disease, this can boost the demand for sepsis diagnostics, which could surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Moreover, another key factor that is responsible for the growth of sepsis diagnostics is the rise in the geriatric population, as per the data published by the WHO in the year 2023, it was estimated that between the years 2015-2050 the number of citizens who aged 60 years and above will get doubled from 12-22% and will reach 2.1 billion by the year 2050. Adding to it, by the year 2030, one out of every six individuals worldwide will age 60 years or more. As per the above-mentioned data, the number of citizens aged 80 years or over is expected to get triple between the years 2020 and 2050 & will reach 426 million population. Furthermore, as age increases chances of suffering from infections also increase due to weakening immune systems which can boost the demand for sepsis diagnosis. Therefore, the rising geriatric population increases the demand for sepsis diagnostics, this surge the sepsis diagnostics overall market forward during the forecast period (2024-2030).

Therefore, the aforementioned factors could increase the demand for sepsis diagnostics, which can surge the growth of the overall sepsis diagnostics market during the forecast period from 2024-2030.

However, the high cost of sepsis treatment and the lack of awareness & knowledge about sepsis can hamper the global sepsis diagnostics market growth.

The ongoing COVID-19 epidemic has slightly positively impacted the sepsis diagnostics market. According to the Global Sepsis Alliance, SARS-CoV-2 causes sepsis. This is reinforced by a recent study, which found that viral sepsis is the most common complication in COVID-19 patients and is linked to increased mortality. Since, COVID-19 affects the patient's respiratory system, with the majority of patients requiring hospitalization for pneumonia of various severity, nonetheless, almost all other organ systems can be impacted. This is consistent with a mix of sepsis and direct viral invasion. Thus, the surge in COVID-19 pandemic cases boosted the demand for sepsis diagnostics, and the further increase in the COVID-19 cases is expected to increase the demand for tools, reagents, and test kits for sepsis detection, resulting in the surge in sepsis diagnostics overall market.

Sepsis Diagnostics Market Segment Analysis:

Sepsis Diagnostics Market by Techniques Type (Immunoassay, Molecular Diagnosis, Microbiology, Flow Cytometry, and Others), Test Type (Laboratory Testing and Point Of Care Testing), Product Type (Assays & Reagents, Instruments & Kits), Pathogen (Bacterial, Fungal, and Others), End-User (Hospitals, Pathology Laboratories, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the sepsis diagnostics market, the instruments & kits segment is expected to show significant growth during the forecast from 2024-2030. For instance, the Blood Culture Identification Panel (BCID), allows for the quick as well as precise identification of pathogens and antibiotic resistance genes associated with bloodstream infections. It looks for a wide range of pathogens (24) as well as 3 antibiotic resistance genes linked to bloodstream infections. Moreover, in roughly an hour, with only 2 minutes of hands-on work, it helps to identify infections in 9 out of 10 positive blood cultures with just one test. Thus, the benefits associated with the BCID, uplift the instruments & kits demand in the market, which could drive the growth of the overall global sepsis diagnostics market during the forecast period.

Furthermore, the developments in sepsis diagnostics products, are also expected to drive the market growth for it. For instance, in May 2022, BioMerieux, a global pioneer in-vitro diagnostics player, gained clearance from Health Canada for its BIOFIRE® Blood Culture Identification 2 (BCID2) Panel. In comparison to the original BIOFIRE® BCID Panel, the BIOFIRE® BCID2 Panel for quick molecular diagnosis of bloodstream infection contains numerous more pathogens, an extended list of antibiotic resistance genes, and many altered targets.

Hence, due to the interplay of the factors mentioned above, the sepsis diagnostics demand increases in the market, which can drive the growth of the global sepsis diagnostics market during the forecast period.

North America is expected to dominate the overall Sepsis Diagnostics Market:

Among all the regions, North America is expected to dominate the global sepsis diagnostics market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the increasing prevalence of bacterial infections such as tuberculosis and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products are expected to increase the demand for sepsis diagnostics in the North America market.

According to the Centers for Disease Control and Prevention (CDC) published data in the year 2023, in the year 2023, the number of Tuberculosis (TB) cases in the United States was 7,860 which is equivalent to 2.4 per 100,000 persons. Thus, tuberculosis could lead to sepsis shock, which can result in improved demand for sepsis diagnostics, contributing to the conductive growth for sepsis diagnostics overall market forecast from 2024-2030.

Moreover, the surge in regulatory approvals for technologically advanced sepsis diagnostics products can boost the sepsis diagnostics overall market in the region. For instance, in February 2022, Noninvasix, which is expected to be the first company to non-invasively monitor central venous oxygenation announced that its LIVOx(TM) Central Venous Oxygenation Monitor has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for non-invasive, real-time, continuous or spot monitoring of central venous oxygen saturation (ScvO2) in adults at risk of septic shock in the United States.

Therefore, with the interplay of the factors mentioned above, there will be high demand for sepsis diagnostics, which would provide a conducive growth environment for the North American region in the sepsis diagnostics market.

Sepsis Diagnostics Market Key Players:

Some of the key market players operating in the sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

Recent Developmental Activities in the Sepsis Diagnostics:

In January 2022, Pathogenomix, a next-generation sequencing, pathogen diagnostic company, was granted US Food and Drug Administration (FDA) Breakthrough Device Designation for its Patho-Seq assay. The assay is designed for the quick detection and identification of hundreds of clinically important bacteria for a wide range of clinical diseases and sample types, including sepsis from whole blood samples and bacterial meningitis from Cerebrospinal Fluid (CSF).

In November 2022, Immunexpress Inc, a molecular diagnostic company focusing on improving outcomes for suspected sepsis patients, announced that SeptiCyte RAPID has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). In hospitalized patients suspected of sepsis, the approved test helps to distinguish sepsis from infection-free systemic inflammation.

In March 2020, Immunexpress, Inc., a molecular diagnostics company focusing on improving outcomes for patients with suspected sepsis, announced that SeptiCyte® RAPID, their host response technology, has achieved CE Marking. SeptiCyte® RAPID combines SeptiCyte® technology with the Biocartis Idylla platform to provide actionable data in less than an hour, which allows doctors to make better patient care decisions. SeptiCyte® RAPID is a gene expression test that quantifies the relative expression levels of host response genes extracted from whole blood collected in the PAXgene® Blood RNA Tube using reverse transcription-polymerase chain reaction (PCR).

Key Takeaways from the Sepsis Diagnostics Market Report Study

  • Market size analysis for current sepsis diagnostics market (2023), and market forecast for 5 years (2024-2030)
  • The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the sepsis diagnostics market
  • Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint venture happened over the last 3 years
  • Key companies dominating the global sepsis diagnostics
  • Various opportunities available for the other competitor in the sepsis diagnostics market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030.
  • Which are the top-performing regions and countries in the current sepsis diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for sepsis diagnostics market growth in the coming future?

Target Audience who can be benefited from this Sepsis Diagnostics Market Report Study

  • Sepsis diagnostics providers
  • Research organizations and consulting companies
  • Sepsis Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in sepsis diagnostics
  • Various end-users who want to know more about the sepsis diagnostics market and latest technological developments in the sepsis diagnostics

Frequently Asked Questions for Sepsis Diagnostics:

1. What are Sepsis Diagnostics?

Sepsis diagnostics includes instruments, lab tests, various technologies, and others, which are used to diagnose sepsis by checking signs of infection or organ damage within the patient.

2. What is the market for Global Sepsis Diagnostics?

The global sepsis diagnostics market was valued at USD 644.48 million in 2023, growing at a CAGR of 9.60% during the forecast period from 2024 to 2030 to reach USD 1114.82 million by 2030.

3. What are the drivers for the Global Sepsis Diagnostics Market?

The sepsis diagnostics market is witnessing positive market growth owing to the factors such as the increasing prevalence of the COVID-19 pandemic, a rise in the geriatric population, the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for the technologically advanced sepsis diagnostics products

4. Who are the key players operating in the Sepsis Diagnostics Market?

Some of the key market players operating in the Sepsis diagnostics market include BD, Cytovale(TM) Inc, Thermo Fisher Scientific Inc, Abbott, F. Hoffmann-La Roche Ltd, bioMerieux SA, Danaher, T2 Biosystems Inc, Luminex Corporation, Bruker, Immunexpress Inc, Axis-Shield Diagnostics Ltd, Quidel Corporation, Siemens Healthcare Private Limited, EKF Diagnostics Holdings plc, Seegene Inc, Boditech Med Inc, Alifax S.r.l. Italy, Koninklijke Philips N.V, Response Biomedical Corp, and others.

5. Which region has the highest share in Sepsis Diagnostics Market?

North America is expected to dominate the global sepsis diagnostics market. Factors contributing to the growth are the increasing prevalence of bacterial infections such as tuberculosis, and the surge in the regulatory approvals for technologically advanced sepsis diagnostics products contributes to the growth of the sepsis diagnostics market in the North America region.

Table of Contents

1.Sepsis Diagnostics Market Report Introduction

2. Sepsis Diagnostics Market Executive Summary

  • 2.1. Scope of the Study
  • 2.2. Market at Glance
  • 2.3. Competitive Assessment
  • 2.4. Financial Benchmarking

3. Regulatory Analysis

  • 3.1. The US
  • 3.2. Europe
  • 3.3. Japan
  • 3.4. China

4. Sepsis Diagnostics Market Key Factors Analysis

  • 4.1. Sepsis Diagnostics Market Drivers
    • 4.1.1. The Increasing Prevalence of COVID-19 Pandemic
    • 4.1.2. ARise in the Geriatric Population
    • 4.1.3. The Increasing Prevalence of Bacterial Infections such as Tuberculosis
    • 4.1.4. The Surge in the Regulatory Approvals for the Technologically Advanced Sepsis Diagnostics Products
  • 4.2. Sepsis Diagnostics Market Restraints And Challenges
    • 4.2.1. The High Cost of Sepsis Treatment
    • 4.2.2. The Lack of Awareness & Knowledge about Sepsis
  • 4.3. Sepsis Diagnostics Market Opportunities
    • 4.3.1. The Emerging Technologies for Laboratory and Point of Care Testing
    • 4.3.2. The Identification of Novel Biomarkers for Sepsis Diagnosis

5. Sepsis Diagnostics Market Porter's Five Forces Analysis

  • 5.1. Bargaining Power of Suppliers
  • 5.2. Bargaining Power of Consumers
  • 5.3. Threat of New Entrants
  • 5.4. Threat of Substitutes
  • 5.5. Competitive Rivalry

6. COVID-19 Impact Analysis on Sepsis Diagnostics Market

7. Sepsis Diagnostics Market Layout

  • 7.1. By Product Type
    • 7.1.1. Assays & Reagents
    • 7.1.2. Instruments & Kits
  • 7.2. By Techniques Type
    • 7.2.1. Immunoassay
    • 7.2.2. Molecular Diagnosis
    • 7.2.3. Flow Cytometry
    • 7.2.4. Microbiology
    • 7.2.5. Others
  • 7.3. By Test Type
    • 7.3.1. Laboratory Testing
    • 7.3.2. Point Of Care Testing
  • 7.4. By Pathogen
    • 7.4.1. Bacterial
    • 7.4.2. Fungal
    • 7.4.3. Others
  • 7.5. By End-User
    • 7.5.1. Hospitals
    • 7.5.2. Pathology Laboratories
    • 7.5.3. Others
  • 7.6. By Geography
    • 7.6.1. North America
      • 7.6.1.1. United States Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.1.2. Canada Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.1.3. Mexico Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.2. Europe
      • 7.6.2.1. France Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.2. Germany Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.3. United Kingdom Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.4. Italy Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.5. Spain Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.6. Russia Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.2.7. Rest of Europe Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.3. Asia-Pacific
      • 7.6.3.1. China Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.2. Japan Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.3. India Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.4. Australia Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.5. South Korea Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.3.6. Rest of Asia Pacific Sepsis Diagnostics Market Size in USD Million (2021-2030)
    • 7.6.4. Rest of the World (RoW)
      • 7.6.4.1. Middle East Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.4.2. Africa Sepsis Diagnostics Market Size in USD Million (2021-2030)
      • 7.6.4.3. South America Sepsis Diagnostics Market Size in USD Million (2021-2030)

8. Sepsis Diagnostics Market Global Company Share Analysis - Key 3-5 Companies

9. Sepsis Diagnostics Market Company and Product Profiles

  • 9.1. BD
    • 9.1.1. Company Overview
    • 9.1.2. Company Snapshot
    • 9.1.3. Financial Overview
    • 9.1.4. Product Listing
    • 9.1.5. Entropy
  • 9.2. Cytovale(TM) Inc
    • 9.2.1. Company Overview
    • 9.2.2. Company Snapshot
    • 9.2.3. Financial Overview
    • 9.2.4. Product Listing
    • 9.2.5. Entropy
  • 9.3. Thermo Fisher Scientific Inc
    • 9.3.1. Company Overview
    • 9.3.2. Company Snapshot
    • 9.3.3. Financial Overview
    • 9.3.4. Product Listing
    • 9.3.5. Entropy
  • 9.4. Abbott
    • 9.4.1. Company Overview
    • 9.4.2. Company Snapshot
    • 9.4.3. Financial Overview
    • 9.4.4. Product Listing
    • 9.4.5. Entropy
  • 9.5. F. Hoffmann-La Roche Ltd
    • 9.5.1. Company Overview
    • 9.5.2. Company Snapshot
    • 9.5.3. Financial Overview
    • 9.5.4. Product Listing
    • 9.5.5. Entropy
  • 9.6. bioMerieux SA
    • 9.6.1. Company Overview
    • 9.6.2. Company Snapshot
    • 9.6.3. Financial Overview
    • 9.6.4. Product Listing
    • 9.6.5. Entropy
  • 9.7. Danaher
    • 9.7.1. Company Overview
    • 9.7.2. Company Snapshot
    • 9.7.3. Financial Overview
    • 9.7.4. Product Listing
    • 9.7.5. Entropy
  • 9.8. T2 Biosystems Inc
    • 9.8.1. Company Overview
    • 9.8.2. Company Snapshot
    • 9.8.3. Financial Overview
    • 9.8.4. Product Listing
    • 9.8.5. Entropy
  • 9.9. Luminex Corporation
    • 9.9.1. Company Overview
    • 9.9.2. Company Snapshot
    • 9.9.3. Financial Overview
    • 9.9.4. Product Listing
    • 9.9.5. Entropy
  • 9.10. Bruker
    • 9.10.1. Company Overview
    • 9.10.2. Company Snapshot
    • 9.10.3. Financial Overview
    • 9.10.4. Product Listing
    • 9.10.5. Entropy
  • 9.11. Immunexpress Inc
    • 9.11.1. Company Overview
    • 9.11.2. Company Snapshot
    • 9.11.3. Financial Overview
    • 9.11.4. Product Listing
    • 9.11.5. Entropy
  • 9.12. Axis-Shield Diagnostics Ltd
    • 9.12.1. Company Overview
    • 9.12.2. Company Snapshot
    • 9.12.3. Financial Overview
    • 9.12.4. Product Listing
    • 9.12.5. Entropy
  • 9.13. Quidel Corporation
    • 9.13.1. Company Overview
    • 9.13.2. Company Snapshot
    • 9.13.3. Financial Overview
    • 9.13.4. Product Listing
    • 9.13.5. Entropy
  • 9.14. Siemens Healthcare Private Limited
    • 9.14.1. Company Overview
    • 9.14.2. Company Snapshot
    • 9.14.3. Financial Overview
    • 9.14.4. Product Listing
    • 9.14.5. Entropy
  • 9.15. EKF Diagnostics Holdings plc
    • 9.15.1. Company Overview
    • 9.15.2. Company Snapshot
    • 9.15.3. Financial Overview
    • 9.15.4. Product Listing
    • 9.15.5. Entropy
  • 9.16. Seegene Inc
    • 9.16.1. Company Overview
    • 9.16.2. Company Snapshot
    • 9.16.3. Financial Overview
    • 9.16.4. Product Listing
    • 9.16.5. Entropy
  • 9.17. Boditech Med Inc
    • 9.17.1. Company Overview
    • 9.17.2. Company Snapshot
    • 9.17.3. Financial Overview
    • 9.17.4. Product Listing
    • 9.17.5. Entropy
  • 9.18. Alifax S.r.l. Italy
    • 9.18.1. Company Overview
    • 9.18.2. Company Snapshot
    • 9.18.3. Financial Overview
    • 9.18.4. Product Listing
    • 9.18.5. Entropy
  • 9.19. Koninklijke Philips N.V
    • 9.19.1. Company Overview
    • 9.19.2. Company Snapshot
    • 9.19.3. Financial Overview
    • 9.19.4. Product Listing
    • 9.19.5. Entropy
  • 9.20. Response Biomedical Corp
    • 9.20.1. Company Overview
    • 9.20.2. Company Snapshot
    • 9.20.3. Financial Overview
    • 9.20.4. Product Listing
    • 9.20.5. Entropy

10. KOL Views

11. Project Approach

12. About DelveInsight

13. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: COVID-19 Impact Analysis
  • Table 3: Sepsis Diagnostics Market in Global (2021-2030)
  • Table 4: Sepsis Diagnostics Market in Global by Product Type (2021-2030)
  • Table 5: Sepsis Diagnostics Market in Global by Techniques Type (2021-2030)
  • Table 6: Sepsis Diagnostics Market in Global by Test Type (2021-2030)
  • Table 7: Sepsis Diagnostics Market in Global by Pathogen (2021-2030)
  • Table 8: Sepsis Diagnostics Market in Global by End-User (2021-2030)
  • Table 9: Sepsis Diagnostics Market in Global by Geography (2021-2030)
  • Table 10: Sepsis Diagnostics Market in North America (2021-2030)
  • Table 11: Sepsis Diagnostics Market in North America by Country (2021-2030)
  • Table 12: Sepsis Diagnostics Market in the US (2021-2030)
  • Table 13: Sepsis Diagnostics Market in Canada (2021-2030)
  • Table 14: Sepsis Diagnostics Market in Mexico (2021-2030)
  • Table 15: Sepsis Diagnostics Market in Europe (2021-2030)
  • Table 16: Sepsis Diagnostics Market in Europe by Country (2021-2030)
  • Table 17: Sepsis Diagnostics Market in France (2021-2030)
  • Table 18: Sepsis Diagnostics Market in Germany (2021-2030)
  • Table 19: Sepsis Diagnostics Market in the United Kingdom (2021-2030)
  • Table 20: Sepsis Diagnostics Market in Italy (2021-2030)
  • Table 21: Sepsis Diagnostics Market in Spain (2021-2030)
  • Table 22: Sepsis Diagnostics Market in Russia (2021-2030)
  • Table 23: Sepsis Diagnostics Market in Rest of Europe (2021-2030)
  • Table 24: Sepsis Diagnostics Market in APAC (2021-2030)
  • Table 25: Sepsis Diagnostics Market in APAC by Country (2021-2030)
  • Table 26: Sepsis Diagnostics Market in China (2021-2030)
  • Table 27: Sepsis Diagnostics Market in Japan (2021-2030)
  • Table 28: Sepsis Diagnostics Market in India (2021-2030)
  • Table 29: Sepsis Diagnostics Market in Australia (2021-2030)
  • Table 30: Sepsis Diagnostics Market in South Korea (2021-2030)
  • Table 31: Sepsis Diagnostics Market in Rest of APAC (2021-2030)
  • Table 32: Sepsis Diagnostics Market in Rest of World (2021-2030)
  • Table 33: Sepsis Diagnostics Market in RoW by Region (2021-2030)
  • Table 34: Sepsis Diagnostics Market in Middle East (2021-2030)
  • Table 35: Sepsis Diagnostics Market in Africa (2021-2030)
  • Table 36: Sepsis Diagnostics Market in South America (2021-2030)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: COVID-19 Impact Analysis
  • Figure 3: Sepsis Diagnostics Market in Global (2021-2030)
  • Figure 4: Sepsis Diagnostics Market in Global by Product Type (2021-2030)
  • Figure 5: Sepsis Diagnostics Market in Global by Techniques Type (2021-2030)
  • Figure 6: Sepsis Diagnostics Market in Global by Test Type (2021-2030)
  • Figure 7: Sepsis Diagnostics Market in Global by Pathogen (2021-2030)
  • Figure 8: Sepsis Diagnostics Market in Global by End-User (2021-2030)
  • Figure 9: Sepsis Diagnostics Market in Global by Geography (2021-2030)
  • Figure 10: Sepsis Diagnostics Market in North America (2021-2030)
  • Figure 11: Sepsis Diagnostics Market in North America by Country (2021-2030)
  • Figure 12: Sepsis Diagnostics Market in the US (2021-2030)
  • Figure 13: Sepsis Diagnostics Market in Canada (2021-2030)
  • Figure 14: Sepsis Diagnostics Market in Mexico (2021-2030)
  • Figure 15: Sepsis Diagnostics Market in Europe (2021-2030)
  • Figure 16: Sepsis Diagnostics Market in Europe by Country (2021-2030)
  • Figure 17: Sepsis Diagnostics Market in France (2021-2030)
  • Figure 18: Sepsis Diagnostics Market in Germany (2021-2030)
  • Figure 19: Sepsis Diagnostics Market in the United Kingdom (2021-2030)
  • Figure 20: Sepsis Diagnostics Market in Italy (2021-2030)
  • Figure 21: Sepsis Diagnostics Market in Spain (2021-2030)
  • Figure 22: Sepsis Diagnostics Market in Russia (2021-2030)
  • Figure 23: Sepsis Diagnostics Market in Rest of Europe (2021-2030)
  • Figure 24: Sepsis Diagnostics Market in APAC (2021-2030)
  • Figure 25: Sepsis Diagnostics Market in APAC by Country (2021-2030)
  • Figure 26: Sepsis Diagnostics Market in China (2021-2030)
  • Figure 27: Sepsis Diagnostics Market in Japan (2021-2030)
  • Figure 28: Sepsis Diagnostics Market in India (2021-2030)
  • Figure 29: Sepsis Diagnostics Market in Australia (2021-2030)
  • Figure 30: Sepsis Diagnostics Market in South Korea (2021-2030)
  • Figure 31: Sepsis Diagnostics Market in Rest of APAC (2021-2030)
  • Figure 32: Sepsis Diagnostics Market in Rest of World (2021-2030)
  • Figure 33: Sepsis Diagnostics Market in RoW by Region (2021-2030)
  • Figure 34: Sepsis Diagnostics Market in Middle East (2021-2030)
  • Figure 35: Sepsis Diagnostics Market in Africa (2021-2030)
  • Figure 36: Sepsis Diagnostics Market in South America (2021-2030)
  • Figure 37: Market Drivers
  • Figure 38: Market Barriers
  • Figure 39: Market Opportunities
  • Figure 40: PORTER'S Five Force Analysis